Arshad Hydra's questions to XOMA Royalty (XOMA) leadership • Q4 2015
Question
Arshad Hydra of RBC Capital Markets questioned the R&D expenditure outlook for 2016 compared to 2015 and asked for details on the number of clinical trial centers for the congenital hyperinsulinism study.
Answer
CFO Tom Burns projected that total 2016 expenses would be approximately 30% lower than in 2015, with a 75% R&D and 25% SG&A split. CEO John Varian and SVP Paul Rubin clarified that while two centers are currently active, XOMA is in discussions with all 10-12 major global centers to expand patient access for future trials.